May - 2022

top of page

Developing safe, convenient, disease-modifying treatments for food allergies.

Aravax appoints Dr Brett Haumann to Board of Directors

06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy...

bottom of page